Effect of Danhong Injection (丹红注射液) on Improving Coronary Microcirculation Injury after Percutaneous Coronary Intervention

Objective: To explore the effectiveness of Danhong Injection (丹红注射液) on improving microcirculatory injury after percutaneous coronary intervention (PCI) in patients with coronary heart disease (CHD). Methods: A randomized controlled trial was conducted and 90 patients were enrolled. A random sequence was generated using statistical analysis software. Patients with microcirculatory injuries after PCI were randomly divided into 3 groups for treatment (30 subjects in each group): Danhong Injection group: after PCI, Danghong Injections were given with intravenous administration with 40 mL twice a day for a week; statins intensive group: after PCI, atorvastatin calcium tablets were given oral medication with 80 mg once, and then atorvastatin 40 mg daily for 1 week; the control group: after PCI, atorvastatin calcium tablets were given oral medication with 10–20 mg daily for 1 week. The index of microcirculation resistance (IMR) was used to assess microcirculatory injury during PCI. The IMR of the target vessel was reexamined after 1 week of drug treatment. Results: After one week''s drug treatment, IMR was significantly decreased in both statins intensive group and Danhong Injection group compared with the control group (P<0.01), but no difference was found between statins intensive group and Danhong injection group (14.03± 2.54 vs. 16.03± 5.72 U, P=0.080). Conclusions: The efficacy of Danhong Injection is non-inferior to statin. Early use of Danhong Injection after PCI can effectively improve coronary microcirculation injury after PCI.     

Effect of Tongguan Capsules(通冠胶囊)on Restenosis after Coronary Stent Implantation:Study Protocol for A Randomized Controlled Trial

Background:Although percutaneous coronary intervention(PCI)had become widely employed therapeutic procedure for coronary artery disease,stent restenosis limited the benefits of this revascularization and the question how to prevent such events remained unresolved.While numerous empirical observations suggested Tongguan Capsules(通冠胶囊),a patented Chinese Medicine,could decrease frequency and duration of angina pectoris attacks,evidence supporting its efficacy on restenosis remained inadequate.Objective:This trial was designed to determine whether Tongguan Capsules would reduce restenosis rate in patients after successful stent implantation.Methods:Approximately 400 patients undergoing percutaneous coronary stent deployment were enrolled and randomized to control group or Tongguan Capsules(4.5 g/d)for 3 months.All patients received standard anti-platelet,anti-coagulation and lipid-decreasing treatments,concurrently.The primary clinical endpoint was the 12-month incidence of the major adverse cardiovascular events(defined as cardiac death,myocardial infarction,and recurrence of symptoms requiring additional revascularization).The angiographic end point was restenosis rate at 6 months.Conclusion:This study would provide important evidence for the use of Tongguan Capsules in patients after stent implantation in combination with routine therapies,which may significantly reduce incidence of the restenosis so as to potentially improve the clinical outcomes.(registration number:ChiCTR-TRC-ChiCTR-IIR-17011407)     

Angiographic Observation of Immediate Effect of Electric Pulse Stimulation at Zhiyang Point on Coronary Artery

Angiographic Observation of Immediate Effect of Electric Pulse Stimulation at Zhiyang Point on Coronary Artery@颜红兵@柯元南@舒邦明@欧知宏@赵霞@赵桂茹     

Clinical Study of Xiongshao Capsule (芎芍胶囊) in Preventing Restenosis after Coronary Interventional Treatment

Ｓｉｎｃｅｐｅｒｃｕｔａｎｅｏｕｓｔｒａｎｓｌｕｍｉｎａｌｃｏｒｏｎａｒｙａｎｇｉｏｐｌａｓｔｙ（ＰＴＣＡ）ａｎｄ／ｏｒｃｏｒｏｎａｒｙｓｔｅｎｔｉｎｇｃａｎｒｅｃｏｎｓｔｒｕｃｔｃｏｒｏｎａｒｙｂｌｏｏｄｃｉｒｃｕｌａｔｉｏｎｗｉｔｈ ｏｕｔｔｈｏｒａｃ     

Complete Revascularization of Coronary Artery

Twenty five casses of complete revascularization for coronary artery discase by sequential aortocoronary saphaneous bypass operation were performed from April 1990 to July 1993.     

Experimental Study of Salvia Miltiorrhiza on the Prevention of Restenosis after Angioplasty

Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｓｔｕｄｙ　ｏｆ　Ｓａｌｖｉａ　Ｍｉｌｔｉｏｒｒｈｉｚａ　ｏｎ　ｔｈｅ　Ｐｒｅｖｅｎｔｉｏｎ　ｏｆ　Ｒｅｓｔｅｎｏｓｉｓ　ａｆｔｅｒ　ＡｎｇｉｏｐｌａｓｔｙＺＨＯＵＸｉａｏ－ｍｉｎｇ，ＬＵＺａｉ－ｙｉｎｇａｎｄＷＡＮＧＤａｏ...     

Clinical Study on Effect of Garlicin in Stabilizing the Carotid Artery Atherosclerotic Plaque in Patients with Primary Hypertension and Coronary Artery Disease

Objective:To investigate the effect of garlicin in treating carotid artery atherosclerotic plaque (GAAP) in patients with primary hypertension and coronary heart disease (PHT-CHD).Methods:Seventynine patients with PHT-CHD were randomly divided into the treated group (39 patients) treated with garlicin and fosinopril and the control group (40 patients) treated with fosinopril alone. The change of CAAP was evaluated by high frequency ultrasonic examination every six months, and the changes of intercellular adhesion molecule-1 (ICAM-1) and high sensitive C-reactive protein (hs-CRP) were measured by ELISA, with the observation proceeding for 52 weeks totally. Results:By the end of the experiment, the number of complex plaques, Crouse integrals, intima-media thickness, serum ICAM-1 and hs-CRP were significantly lower in the treated group than those in the control group with significant difference (P<0.05). Conclusion:Garlicin could stabilize CMP to a certain extent and shows a definite vascular protective effect in patients with PHT-CHD.     

Study on Influence of Sini Decoction (四逆汤) on Quality of Life of Patients after Percutane ous Transluminal Coronary Angioplasty

Ｐｅｒｃｕｔａｎｅｏｕｓｔｒａｎｓｌｕｍｉｎａｌｃｏｒｏｎａｒｙａｎｇｉｏｐｌａｓｔｙ（ＰＴＣＡ）ｉｓｏｎｅｏｆｔｈｅｍａｉｎｍｅｔｈｏｄｓｆｏｒｒｅｌｉｅｖｉｎｇｍｙｏｃａｒｄｉａｌｉｓｃｈｅｍｉａｉｎｃｏｒｏｎａｒｙｈｅａｒｔｄｉｓｅａｓｅｃｌｉｎｉｃａｌｌｙ．ＴｈｅｌａｒｇｅａｍｏｕｎｔｏｆｔｏｘｉｃｆｒｅｅｒａｄｉｃａｌｓｐｒｏｄｕｃｅｄｂｙＰＴＣＡｃｏｕｌｄｉｎｄｕｃｅｈａｒｍｆｕｌｌｉｐｉｄｐｅｒｏｘｉｄａｔｉｏｎ（ＬＰＯ）．Ｔｈｅａｕｔｈｏｒｓ＇ｐｒｅｌｉｍｉｎａｒｙｓｔｕｄｙｈａ…     

Clinical Observation on Shu Xin Yi Mai Capsules for Prevention of Recurrent Stricture after Coronary Artery Introducing Treatment

Shu Xin Yi Mai Capsules (舒心益脉胶囊) combined with western medicine was used in the routinetreatment of 22 cases who successfully received coronary artery introducing therapy (Chinese-westernmedicine group),and the results was compared with the 26 cases treated routinely with simple westernmedicine in the control group (western medicine group).It was found that both the recurrence rate of anginapectoris and the incidence rate of recurrent stricture in the Chinese-western medicine group were significantlylower than that in the control group (both P<0.05).There was no significant difference between the twogroups in expression of platelet activating molecules CD62P (a-granular membrane protein),CD63(lysosome intact membrane protein) and CD41 (glucoprotein IIb) before the treatment,but with a significantdifference after the treatment (P<0.05).     

Does Percutaneous Coronary Intervention on Off Days have an Effect on Long-term Prognosis in Patients with Coronary Artery Disease in China?

As generally known, many hospitals provide routine care on weekdays but only emergency or urgent care on holidays and weekends. Hospital staffing is numerically reduced on holidays and weekends, as well as the available expertise on duty. The onset of acute myocardial infarction (AMI) on off days was reported to be associated with higher short-term mortality[1,2]. A similar phenomenon was also observed in patients with emergent diseases who were admitted on weekends and in the nighttime, as well as those who received elective procedures on weekends[3-5].     

Experimental Study of Adenovirus Vector Mediated-hVEGF165 Gene on Prevention of Restenosis after Angioplasty

This study evaluated the effects of adenovirus vector mediated human vascular endotheli-al growth factor-165 (hVEGF165) gene on prevention of restenosis after angioplasty. Rabbit models of bilateral carotid artery injury were established by balloon denudation. The recombinant adenovi-ruses containing hVEGF165 cDNA was directly injected into left side of the injured carotid arteries.On day 3 and week 3 after transfection the expression of VEGF was observed by RT-PCR and im-munohistochemistry. The thrombokinesis, reendothelialization (rET) and intimal hyperplasia in ca-rotid arteries were evaluated by computerized image analysis system 3 weeks after gene transfer,The changes in the VEGF gene-treated side were compared with the control side. Our results showed that 3 days and 3 weeks after hVEGF165 gene transfer the VEGF mRNA and antigen ex-pression were detected in vivo. 3 weeks after the transfer, the carotid artery rET was markedly better in the VEGF gene-treated group compared with the control. The thrombokinesis, intima are-a/media area (I/M), maximal intimal and medial thicknesses (ITmax and MTmax) demonstrated a statistically significant decrease in arteries treated with VEGF gene as compared with the control group. It is concluded that VEGF gene transfer could be achieved by intra-arterial injection of re-combinant adenoviruses. It might accelerate the restoration of endothelial integrity, inhibit throm-bokinesis and attenuate intimal hyperplasia in the injured arteries after VEGF gene transfer. This procedure could be useful in preventing restenosis after angioplasty.     

Effects of Erigeron Injection on Vascular Endothelium in Patients after Intracoronary Stenting

Objective: To observe the levels of serum C-reactive protein (CRP), endothelin-1 (ET-1), nitric oxide (NO), and superoxide dismutase (SOD) in patients after intracoronary stenting (ICS), and the effects of Erigeron Injection (El) on them. Methods:Seventy-two patients, who received ICS and had symptoms of chest stuffiness, palpitation and chest pain, were randomly divided into two groups, with 36 patients in the control group treated with Plavix alone for anti-platelet aggregation, and the other 36 patients in the treated group treated with Plavix and El in combination. CRP, ET-1, NO and SOD were determined and compared before and 1, 2 and 3 weeks after treatment. Results: As compared with those in the control group, improvement of symptoms in the treated group was significantly better, with the levels of CRP and ET-1 lower and levels of SOD and NO higher or approaching to normal ranges and significant difference was shown between the two groups (P<0.01). Conclusion: El could alleviate uncomfortable feelings such as chest stuffiness in patients after ICS, and improve the function of vascular endothelium.     

Effects of Lüfukang Capsules (律复康胶囊) on Coronary Artery Ligation-Induced Arrhythmia in Dogs

Objective: To observe the effects of Lüfukang Capsules (律复康胶囊 LFKC) on arrhythmia induced by ligation of coronary artery in dogs. Methods: Thirty dogs were randomly divided into 5 groups, the model group administrated with equal volume of distilled water, the positive control group administrated with Wenxin Granules (稳心颗粒), and the small, medium and large dosage LFKC groups, 6 dogs in each group. Thirty minutes after medication, electrocardiogram was conducted and the time of arrhythmia occurrence, times of ventricular premature beat (VP), and incidence rates of ventricular tachycardia (VT) and ventricular fibrillation (VF) were recorded in the model dogs with arrhythmia induced by ligation of coronary artery. Results: Compared with the model group, the occurrence time of arrhythmia induced by the coronary artery ligation in the medium and large LFKC groups was significantly delayed (20.45±9.10 and 19.92±3.78, respectively, both P<0.05). The frequency of VP in the medium and large LFKC groups was also significantly decreased (8.17±6.62 and 3.83±2.79, respectively, both P<0.01). Conclusion: LFKC has anti-arrhythmic effects for the experimental arrhythmia induced by the ligation of coronary artery in dogs.     

Value of Acceleration Flow in the Left Anterior Descending Coronary Artery for the Detection of Coronary Artery Stenosis by Transthoracic Coronary Color Doppler Echocardiography

Transthoracic color Doppler echocardiographyhas been widely used to measure the coronary ar-tery flowvelocity reserve[1].It is useful to providei mportant informationfor diagnosis of coronary ar-tery disease and assessment of curative effect afterpercutaneous coronary artery intervention.Butthis evaluats onlythe effect of the stenosis on coro-nary artery flow velocity reserve during maxi malhyperemia reaction.Hemodynamics demonstratesthat localized flow acceleration is present at thestenotic s…     

Study on Platelet-Derived Growth Factor mRNA and Copper-Zinc Superoxide Dismutase mRNA Expression Changes of Aortic Artery Endothelium with Restenosis after Aortic Artery Dilatation Treated with Buyang Huanwu Decoction

Ｓｔｕｄｙ　ｏｎ　Ｐｌａｔｅｌｅｔ－Ｄｅｒｉｖｅｄ　Ｇｒｏｗｔｈ　Ｆａｃｔｏｒ　ｍＲＮＡ　ａｎｄ　Ｃｏｐｐｅｒ－Ｚｉｎｃ　Ｓｕｐｅｒｏｘｉｄｅ　Ｄｉｓｍｕｔａｓｅ　ｍＲＮＡ　Ｅｘｐｒｅｓｓｉｏｎ　Ｃｈａｎｇｅｓ　ｏｆ　Ａｏｒｔｉｃ　Ａｒｔｅｒｙ　Ｅｎ...     

Rosiglitazone Improving Clinical Outcomes in Type 2 Diabetes with Coronary Artery Disease after Percutaneous Coronary Intervention

Objective Rosiglitazone, an agonist of peroxisome proliferator-activated receptor-γ （PPARγ）, is an insulin- sensitizing antidiabetic agent and inhibits restenosis in animal blood vessels. This study was designed to investigate its effects on clinical outcomes of patients with type 2 diabetes and coronary artery disease （CAD） after percutaneous coronary intervention （PCI）. Methods Patients with diabetes and CAD who had undergone PCI were randomly assigned to a rosiglitazone group or a control group. Patients in the rosiglitazone treatment group were treated with rosiglitazone 1 day before PCI （4mg once daily） and treatment was continued until the 6 months follow-up; while in the control group, patients were treated with placebo 1 day before the procedure and until the 6 months follow-up. Adverse events were death, myocardial infarction and urgent target vessel revascularization within 6 months after PCI. Results Seventy patients in the rosiglitazone group and 66 patients in the control group survived during the follow-up. Baseline characteristics among patients in the two groups were well balanced. There was no significant difference in target vessels or the procedure of stent implantation. Compared with the control group, treatment with rosiglitazone was associated with a lower rate of death, myocardial infarction and urgent target vessel revascularization （5.7% vs 19.7%, P=0.013）. Conclusion Rosiglitazone could reduce the risk of the adverse cardiovascular event and improve clinical outcomes in type 2 diabetes with coronary artery disease after PCI.     

ORIGINAL ARTICLES——Clinical Study on Effect of Garlicin in Stabilizing the Carotid Artery Atherosclerotic Plaque in Patients with Primary Hypertension and Coronary Artery Disease

Objective： To investigate the effect of garlicin in treating carotid artery atherosclerotic plaque （OAAP） in patients with primary hypertension and coronary heart disease （PHT-OHD）. Methods： Seventynine patients with PHT-OHD were randomly divided into the treated group （39 patients） treated with garlicin and fosinopril and the control group （40 patients） treated with fosinopril alone. The change of OAAP was evaluated by high frequency ultrasonic examination every six months, and the changes of intercellular adhesion molecule-1 （IOAM-1） and high sensitive O-reactive protein （hs-ORP） were measured by ELISA, with the observation proceeding for 52 weeks totally. Results： By the end of the experiment, the number of complex plaques, Orouse integrals, intima-media thickness, serum IOAM-1 and hs-ORP were significantly lower in the treated group than those in the control group with significant difference （P〈0.05）. Conclusion： Garlicin could stabilize CAAP to a certain extent and shows a definite vascular protective effect in patients with PHT-CHD.